08:00 , Dec 7, 2015 |  BC Week In Review  |  Company News

The Foundation for AIDS Research infectious news

The Foundation for AIDS Research (amfAR) formed the amfAR Institute for HIV Cure Research at the University of California San Francisco (San Francisco, Calif.) with a five-year, $20 million grant. The funding is part of...
03:11 , Dec 1, 2015 |  BC Extra  |  Clinical News

amfAR establishes HIV institute at UCSF

The Foundation for AIDS Research (amfAR) formed the amfAR Institute for HIV Cure Research at the University of California San Francisco with a five-year, $20 million grant. The funding is part of a $100 million...
02:42 , Jan 8, 2015 |  BC Extra  |  Financial News

Follow-on roundup: Synageva, Five Prime, Cerus

Shares of Synageva BioPharma Corp. (NASDAQ:GEVA), Five Prime Therapeutics Inc. (NASDAQ:FPRX) and Cerus Corp. (NASDAQ:CERS) all rose on Wednesday after the companies raised a total of $427.6 million in follow-ons. Rare disease play Synageva raised...
08:00 , Dec 6, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Neurology Tissue inhibitor of metalloproteinases 3 (TIMP3) Mouse studies suggest TIMP3 could help treat traumatic brain injury (TBI). In a mouse model of TBI, i.v....
07:00 , Sep 17, 2012 |  BC Week In Review  |  Company News

Cerus, American Red Cross, Blood Systems deal

Cerus announced separate deals with the American Red Cross and Blood Systems to commercialize Cerus' Intercept Blood System for plasma to treat thrombotic thrombocytopenic purpura ( TTP ) in the U.S., pending FDA approval. Cerus...
07:00 , Sep 29, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Chronic fatigue syndrome (CFS) Xenotropic murine leukemia virus-related virus (XMRV) A study in human blood samples suggests XMRV does not cause or correlate with...
07:00 , Sep 29, 2011 |  BC Innovations  |  Targets & Mechanisms

Square one in CFS

The Chronic Fatigue Initiative is moving on to new approaches to identify the true cause of chronic fatigue syndrome after a consortium of American researchers failed to reproduce a 2009 study linking CFS to a...
08:00 , Nov 22, 2010 |  BC Week In Review  |  Clinical News

Intercept Blood System for plasma and platelets regulatory update

Swissmedic approved Cerus' Intercept Blood System to inactive blood-borne pathogens in donated plasma components intended for transfusion. The system, which uses amotosalen and ultraviolet light, is already approved for use with platelet components in Switzerland....
07:00 , Aug 30, 2010 |  BC Week In Review  |  Company News

Cerus, BioOne Corp. sales and marketing update

Cerus will reacquire from BioOne commercial rights to Intercept Blood System for plasma and platelets in Japan, China, Taiwan, South Korea, Thailand, Vietnam and Singapore. Cerus said the move allows it to pursue a different...
07:00 , May 17, 2010 |  BioCentury  |  Regulation

Adventitious Detection

Now that an academic researcher using new sequencing technology has detected foreign viral DNA in a live attenuated rotavirus vaccine, vaccine developers would be smart - and may eventually be required - to test all...